The abundance of CXCL13-expressing (CD39+) CD8+ T cells and the expression of CXCL9 in the tumor microenvironment are robust predictors for ICB response in many different primary cancer types, including lung and triple-negative BC22–24,52. The gene discussed is CXCL13; the disease is cancer.